Conferences

A new vaccine of the prostate cancer can give the hope to the men with metasttico cancer of prostate allowing its imunitrios systems to fight the illness. The investigators of the university of Iowa had presented given in the vaccine of adenovirus/PSA (Ad/PSA) during the annual scientific meeting of American the Urological association in Orlando. In recent years, the concept of the vaccine imunoterapia for advanced cancer of prostate has the high level more each become time because the research expanded. The main advances in the field had contributed significantly to the examination of this important therapy of the cancer while the investigators explore ways new to draw out the survival and to improve the quality of life in the patients with metasttica illness.

The investigators present its results in a special conference of the press on May 18, 2008 in the P.m 2:00.

The cancerous cells of the prostate produce a protein known as the prostate-specific antigen (PSA). The objective of the imunoterapia for the metasttica illness is to manipulate the imunitrio system of the body to all identify and to destroy these cancerous cells during the body. The vaccine of Ad/PSA was developed introducing the gene of the PSA in the bacteria and the viruses and using acid deoxyribonucleic immune-stimulatory (ADN) to modulate the antitumorosa reply of the body. To allow the imunitrio system of a patient to produce anti-antigens and cancerous cells of the attack can improve the quality of life and extend the survival. More advanced studies in the rats had demonstrated the effectiveness of the vaccine while it produced anti-PSA strong e, in consequence, the powerful immunity of the cancer of the anti-prostate.

This phase I assay physician I evaluated the performance of the vaccine of Ad/PSA in the men with cancer of measurable metasttico prostate. The patients with D2 or D3 the cancers (medium age 71, 128 medium PSA ng/ml) had been dealt with one three levels of dose of the vaccine and followed with the examinations of physical and clinical chemistry in two and three weeks and two, four, eight and 12 months. The medium continuation age 12 months and the medium survival age 18 months.

After to have received the vaccine, at least 40 percent of the patients had developed immune answers to the PSA, with the antibodies anti-PSA produced in 42 percent of the patients and the answers anti-PSA of cell T in 71 percent. 57 percent of the patients had survived more for much foreseen time of what, with the time of duplication increased in 48 percent. The survival the longest age 71 months - almost six years.

—————————-
The article was adaptou today for the medical notice of the release of the original press.
—————————-

Lubaroff DM, BR of Konety, linking BK, Ratliff TL, Madsen T, Williams R: Results of a phase me experimentation of a vaccine of adenovirus/PSA for the prostate cancer. J Urol, suppl., 2008; 179:184, summary 526.

On American the Urological association: Established in 1902 and hosted close to Baltimore, Maryland, American the Urological association is preeminent the professional organization for urologists, with more than 15,000 members in the entire world. An organization without educational intention to gain, the AUA takes the handle its mission to promote the highest standards of the urolgico care carrying through a great variety of members of the programs and its patients, including UrologyHealth.org, an on-line resource award-winning of the patient instruction, and the Urological American Association Foundation, Incorporation.

Source: Holt Lacey
American Urological association